Solifenacin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Overactive Bladder

• Mirabegron
• Oxybutynin
• Tolterodine

Also listed for Overactive Bladder / Urge Incontinence

• Oxybutynin 5 mg tabs
• Tolterodine 1/2 mg tabs

Other medications in Urology

• Tadalafil
• Tadalafil (BPH)
• Tamsulosin
• Terazosin
• Vardenafil
• Vibegron
• Alfuzosin
• Avanafil

About Solifenacin

Solifenacin is a medication commonly prescribed to manage the bothersome symptoms of overactive bladder (OAB). If you're experiencing urgency, frequent urination, or incontinence, solifenacin could offer significant relief. At TheDrugClub, we believe managing your health shouldn't break the bank, which is why we're committed to making essential medications like solifenacin affordable and accessible.

Understanding Solifenacin for Overactive Bladder

Solifenacin is primarily used to treat the symptoms of overactive bladder (OAB). OAB is a common condition characterized by a sudden, strong urge to urinate that's difficult to defer (urgency), often leading to involuntary leakage of urine (urge incontinence). It can also cause frequent urination, both during the day and at night. Living with OAB can significantly impact daily life, affecting work, social activities, and sleep. Solifenacin helps to reduce these disruptive symptoms, allowing individuals to regain control and improve their quality of life.

How Solifenacin Works

Solifenacin belongs to a class of drugs called anticholinergics. It works by relaxing the smooth muscles of the bladder. Specifically, it blocks the action of acetylcholine, a natural chemical in the body that stimulates bladder contractions. By blocking these signals, solifenacin helps to reduce the involuntary contractions of the bladder muscle, thereby increasing the bladder's capacity and decreasing the urgency and frequency of urination. This mechanism helps to alleviate the core symptoms of OAB, providing relief and greater comfort.

Typical Costs of Solifenacin

The cost of solifenacin can vary widely depending on your insurance coverage, the pharmacy you use, and the dosage prescribed. Without insurance, a typical monthly supply of solifenacin can range from $1

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Solifenacin is approved for (FDA label)

Solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Solifenacin (FDA label)

The 5 mg tablets are white or almost white round film-coated tablets, debossed with “C2” on one side and blank on the other side. The 10 mg tablets are white or almost white round film-coated tablets, debossed with “C77” on one side and blank on the other side. Tablets: 5 mg and 10 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Solifenacin (FDA label)

The most common adverse reactions (> 4% in Solifenacin succinate tablets-treated patients and > placebo-treated patients) were dry mouth and constipation at both 5 mg and 10 mg doses; and urinary tract infection and blurred vision at the 10 mg dose. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact HEC Pharm USA Inc. at 1-800-610-5709 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Solifenacin (FDA label)

Solifenacin succinate is contraindicated in patients: With urinary retention [see Warnings and Precautions ( 5.2 )] , With gastric retention [see Warnings and Precautions ( 5.3 )] , With uncontrolled narrow-angle glaucoma [see Warnings and Precautions ( 5.5 )] , and Who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in Solifenacin succinate tablets. Reported adverse reactions have included anaphylaxis and angioedema [see Adverse Reactions ( 6.2 )] . Urinary retention. ( 4 , 5.2 ) Gastric retention. ( 4 , 5.3 ) Uncontrolled narrow-angle glaucoma. ( 4 , 5.5 ) Hypersensitivity to this product or any of its components. ( 4 , 5.1 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Solifenacin (FDA label)

Angioedema and Anaphylactic Reactions : Promptly discontinue Solifenacin succinate tablets and provide appropriate therapy. ( 5.1 ) Urinary Retention : Solifenacin succinate tablets are not recommended for use in patients with clinically significant bladder outlet obstruction. ( 5.2 ) Gastrointestinal Disorders : Solifenacin succinate tablets are not recommended for use in patients with decreased gastrointestinal motility. ( 5.3 ) Central Nervous System Effects : Somnolence has been reported with solifenacin succinate.

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Solifenacin (FDA label)

CYP3A4 Inhibitors : Do not exceed the 5 mg dose of Solifenacin succinate tablets with concomitant use of strong CYP3A4 inhibitors. ( 7.1 ) 7.1 Strong CYP3A4 Inhibitors Solifenacin is a substrate of CYP3A4. Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [see Clinical Pharmacology ( 12.3 )] . The dosage of Solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 )] .

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.